PDS Biotech Q3 Loss Narrows to $7.6M as PDS0301 Takes Lead

PDS Biotechnology Corporation (Nasdaq: PDSB) reported a third-quarter 2026 net loss of $7.6 million, or $0.11 per basic and diluted share, narrowing from a $9.0 million loss in the same quarter a year earlier, the Princeton, New Jersey-based clinical-stage immunotherapy company announced on 13 November 2026. Research and development spending fell to $2.1 million from $4.6 million, and the company closed an initial PIPE tranche of a financing worth up to $22.3 million led by Nant Capital, LLC. Cash stood at $15.2 million on 30 September 2026.

Context — Why the PDS0301 Pivot Matters Now

The quarter's defining move was strategic rather than financial. PDS Biotech told investors it is now prioritizing PDS0301, its investigational tumor-targeted IL-12 immunocytokine, as its lead development program, a shift from the earlier emphasis on the PDS0101 cancer vaccine platform. Chief executive Frank Bedu-Addo said the company continued to execute that prioritization through the period.

The comparable the company itself supplies is the prior-year quarter. Against Q3 2025, the net loss improved by $1.4 million, and the loss per share improved to $0.11 from $0.19 even though the weighted average share count rose to roughly 71.9 million from roughly 46.9 million. That combination — a wider share base but a smaller per-share loss — reflects both the cost reductions and the equity issued over the intervening year.

The catalyst chain runs through NantWorks. The PIPE led by Nant Capital carries a contingent milestone closing tied to the company's submission to the FDA of a registrational Phase 3 protocol for PDS0301, a design the company says was developed in collaboration with NantWorks. The same agreement gives NantWorks a one-year exclusive right to negotiate an exclusive license for the PDS0101 program.

Governance followed the capital. Patrick Soon-Shiong, founder of NantWorks, and James Banaag joined the board as Nant Capital designees, and three additional pharma veterans — John Dawson CBE, Deborah Ramsdell and Bruce Wendel — were appointed effective 18 October 2026. For a pre-revenue biotech, that is the practical backdrop against which the income statement should be read.

Data — What the Numbers Show

The income statement is a cost story. Total operating expenses were $5.9 million for the quarter, down from $8.1 million a year earlier. R&D accounted for almost all of the decline, falling $2.5 million, which the company attributed to $1.6 million less in clinical trial costs, $0.6 million less in personnel costs and $0.3 million less in manufacturing costs.

General and administrative expenses moved the other way, rising to $3.8 million from $3.6 million. The company attributed the $0.2 million increase to $0.3 million more in professional fees and $0.1 million more in personnel costs, partly offset by $0.2 million less in stock-based compensation.

Metric	Q3 2026	Q3 2025
Net loss	$7.6M	$9.0M
Loss per share	$0.11	$0.19
R&D expense	$2.1M	$4.6M
G&A expense	$3.8M	$3.6M
Total operating expenses	$5.9M	$8.1M
Net interest expense	$1.7M	$0.9M

Interest is the pressure point. Net interest expense widened to $1.7 million from $0.9 million, with interest expense of $1.77 million against interest income of just $42,000. That gap is close to a quarter of the gross operating expense base and reflects debt carried through the period.

The balance sheet shows the trade-off. Cash and cash equivalents fell to $15.2 million from $26.7 million at 31 December 2025, while working capital declined to $13.3 million from $18.8 million. Total assets were $18.6 million against $30.5 million at year-end. Long-term debt, listed at $11.7 million at 31 December 2025, reads as zero at 30 September 2026. Total stockholders' equity rose to $13.5 million from $9.3 million, and the accumulated deficit widened to $241.3 million from $216.6 million.

Analysis — What It Means for Biotech Investors

The read-through is about runway versus dilution. Cash of $15.2 million against a quarterly net loss of $7.6 million implies roughly two quarters of funding at the current burn rate, before any PIPE proceeds are counted. The company did not disclose in the report how much of the up-to-$22.3 million was received at the initial closing, nor the price per share, nor the remaining cash runway. Those are the figures a reader would most want and the report does not supply them.

The PDS0301 prioritization also reframes PDS0101. The VERSATILE-002 Phase 2 results for PDS0101 with pembrolizumab in HPV16-positive recurrent and/or metastatic head and neck cancer were published in JAMA Oncology, and the company holds new patent issuances covering the Versamune platform — JP Patent No. 7909860 in Japan and IN Patent No. 603830 and IL Patent No. 265833 covering HPV16 non-HLA restricted T cell vaccines. Yet the same quarter granted NantWorks a one-year exclusive negotiation right on that program, and the company said it intends to pursue partnerships or externally funded opportunities for PDS0101's Phase 3 development.

The counter-argument is that a lower R&D number is not automatically good news. A $2.5 million year-over-year reduction driven mostly by $1.6 million less in clinical trial costs can reflect programs winding down as easily as efficiency, and the company did not break out which trials drove the decline. The NCI-run PDS0301 studies are externally conducted, which supports the lower spend but also means the company's own disclosure on their progress is limited.

Positioning-wise, PDSB remains a small-cap, event-driven name. Holders are effectively long a binary FDA filing and NantWorks partnership outcome, while the widened interest expense and thin cash balance keep the equity sensitive to any further financing.

Outlook — What to Watch Next

The single named catalyst is the contingent PIPE closing, triggered by the company's submission of a registrational Phase 3 protocol for PDS0301 to the FDA. The report gives no date for that submission, and the closing remains subject to satisfaction or waiver of applicable conditions.

The second is the PDS0101 licensing process. NantWorks holds a one-year exclusive negotiation right, and the company has said it will pursue partnerships or externally funded paths for Phase 3 development of that asset. Any signed license, or the lapse of that window, is a discrete event.

The third is the NCI clinical data flow. The company hosted a key opinion leader event featuring Jonathan M. Hernandez of the National Cancer Institute's Center for Cancer Research, discussing PDS0301 in advanced liver-associated cancers with a focus on the metastatic colorectal cancer cohort. Further cohort data from those investigator-run trials is the visible pipeline.

On the balance sheet, cash of $15.2 million is the level to track. The report does not disclose a runway figure, so the quarterly cash print is the only hard marker investors have.

Frequently Asked Questions

What does the PDS Biotech Q3 2026 loss mean for retail investors?

It means the company is spending less but still burning cash faster than it earns, which for a pre-revenue biotech is normal. The $7.6 million net loss against $15.2 million of cash implies roughly two quarters of funding at that rate, excluding any PIPE proceeds. The key variable is how much of the up-to-$22.3 million financing was actually received at the initial closing, which the report does not state.

Why did PDS Biotech's R&D expense fall so sharply?

The company attributed the $2.5 million year-over-year decline to three items: $1.6 million less in clinical trial costs, $0.6 million less in personnel costs and $0.3 million less in manufacturing costs. Much of the PDS0301 clinical work is run by the National Cancer Institute rather than in-house, which supports a lower internal spend. The report does not break out which specific trials drove the reduction.